CYTH News and Press, Cyclo Therapeutics Inc. From 06/17/21

Cyclo Therapeutics (CYTH) jumps 10% premarket after commencing Phase 3 study (TransportNPC) evaluating Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin, delivered intravenously, for the treatment of Niemann-Pick Disease Type C1 (NPC1), a rare ge...

Global clinical protocol agreed upon by US Food and Drug Administration (FDA) and European Medicines Agency (EMA) Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedic...

- Company dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases - Pivotal Phase 3 study of Trappsol ® Cyclo™ for Niemann-Pick Disease Type C (NPC) on track to commence site acti...

Cyclo Therapeutics (CYTH) will join the Russell 2000 Index following the annual reconstitution of the index, effective June 25 after the close of the U.S. equity markets. "Inclusion in the Russell 2000 Index, which is widely used as a performance benchmark, brings added value, market acc...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today...

Live video webcast presentation with members of the Company’s executive leadership team on Thursday, June 17 th at 12:30 PM ET Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotech...

Annovis Bio ([[ANVS]] +210.3%) has more than tripled in value in reaction to promising Phase 2 results for ANVS401, its lead asset for Alzheimer's disease ((AD)) and Parkinson's disease ((PD)).After 25 days of treatment, patients showed a statistically significant improvement of 4.4...

Gainers: Annovis Bio (ANVS) +250%.Jiuzi Holdings (JZXN) +27%.Longeveron (LGVN) +25%.Wah Fu Education (WAFU) +22%.Mesa Royalty Trust (MTR) +20%.Gracell Biotechnologies (GRCL) +20%.Obalon Therapeutics (OBLN) +16%.Yalla Group (YALA) +16%.VOC Energy Trust (VOC) +12%.Cyclo Therapeut...

- Panel discussion around innovating Alzheimer’s Disease (“AD”) drug development on Wednesday, May 26 th 11:00 AM ET Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage bio...

Cyclo Therapeutics (CYTH): Q1 Net loss of $4M.The Company ended the quarter with approximately $15.5 million of cash.Press Release For further details see: Cyclo Therapeutics reports Q1 results